Yaws
14
0
0
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
50%
7 trials in Phase 3/4
25%
3 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (14)
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Integrating Mental Health Into Neglected Tropical Disease Care in Ghana
Evaluation of a LAMP Assay for T. Pallidum. Pertenue
Repurposing Clinically Approved Drugs for Yaws with an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)
Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication
An Accessible Low-cost Plant Treatment for Cutaneous Ulcers
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
Comparison of Two Different Doses of Azithromycin for Treatment of Yaws
Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea
Dual Point-of-care Test for the Diagnosis of Yaws
Single-dose Azithromycin for the Treatment of Yaws